SABS Earnings — SAB Biotherapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
SABS — SAB Biotherapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$3.59
Market Cap$275.3M
P/E—
52W Range$1.60 – $6.60
Next Earnings2026-08-06
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
